A Phase I, open-label, dose finding study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of OBT076, a CD205-directed antibody-drug conjugate, in recurrent and/or metastatic CD205-positive solid tumors and in women with CD205-positive HER2-negative metastatic breast cancer

About this Study

The purpose of this study is to evaluate OBT076, a drug that combines an antibody with the anti-cancer drug.  This study will look at several dose levels of the study drug to find out the highest does level that is safe and well-tolerated and to look at the side effects of the study drug in a small group of people.  OBT076 is experimental.


Sponsor Protocol ID:OBT076-001
IRB Number:2021-0541
Closed for Enrollment
Interventional
Phase 1
September 14, 2023
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion Criteria
  • Must be 18 years of age or older
  • Must recurrent and/or metastatic solid tumors including but not limited to breast cancer, bladder cancer, non small cell lung cancer, gastric cancer and ovarian cancer, whose disease has gotten worse on standard treatment or for which a standard therapy is not available or is no longer working
  • Must have received a maximum of two lines of chemotherapy in metastatic setting
  • Must be able to care for one's self

Exclusion Criteria
  • Has received any chemotherapy within 21 days prior to inclusion in study
  • Has received another investigational (experimental) therapy within 28 days prior to randomization
  • Had major surgery within 14 days prior to starting study treatment or has not recovered from major side effects
  • Has has radiotherapy less than or equal to 4 weeks or limited field radiation for pain control less than or equal to 2 week prior to starting study drug
  • Has not recovered from acute toxic side effects of prior treatment
  • Hs history of, or current symptomatic brain metastasis
  • Has severe renal impairment
  • Has any other malignancy within 5 years prior to randomization
  • Has known history or current diagnosis of HIV infection, unless on triple antiviral treatment with undetectable viral load
  • Lactating or breastfeeding

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:John Henegan
How to participate in our Clinical Trials